Toby Long, MD
Family Medicine · Saginaw, MINPI 1952558272
Payments from drug & device makers
Across 192 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$329
- Otsuka America Pharmaceutical, Inc.$299
- Pfizer$279
- AstraZeneca$267
- Boehringer Ingelheim$232
- GSK$231
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,235100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $329 |
| Otsuka America Pharmaceutical, Inc. | 14 | $299 |
| Pfizer | 25 | $279 |
| AstraZeneca | 20 | $267 |
| Boehringer Ingelheim | 14 | $232 |
| GSK | 13 | $231 |
| Novo Nordisk | 13 | $189 |
| Lilly USA, LLC | 9 | $130 |
| Mylan Specialty L.p. | 5 | $104 |
| Biohaven Pharmaceuticals, Inc. | 3 | $91 |
| Bayer | 5 | $87 |
| Amgen | 5 | $84 |
| Astellas Pharma US Inc | 4 | $81 |
| Merck | 5 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Dexcom, Inc. | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Cipher Pharmaceuticals US LLC | 1 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Novartis | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Lundbeck LLC | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Boston Scientific | 1 | $24 |
| Organon | 2 | $23 |
| Johnson & Johnson | 1 | $23 |
| Abbott | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| USWM, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
| Gilead | 1 | $11 |
How this compares
$3,249 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $104,939 |
| JardianceEmpagliflozin | 75 | $91,281 |
| TrulicityDulaglutide | 91 | $90,640 |
| FarxigaDapagliflozin Propanediol | 75 | $63,203 |
| EliquisApixaban | 57 | $50,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $43,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $32,995 |
| JanuviaSitagliptin Phosphate | 22 | $25,726 |
| EntrestoSacubitril/Valsartan | 25 | $21,514 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 40 | $17,633 |
| MyrbetriqMirabegron | 29 | $14,542 |
| TradjentaLinagliptin | 17 | $11,371 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $9,461 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,768 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $267 | $113,831168 claims |
| Novo NordiskOzempic | $189 | $104,939110 claims |
| Boehringer IngelheimJardiance, Tradjenta | $232 | $102,65292 claims |
| Lilly USA, LLCTrulicity, Humalog | $130 | $93,787104 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix | $231 | $61,349112 claims |
| PfizerEliquis | $279 | $50,52057 claims |
| MerckJanuvia | $77 | $25,72622 claims |
| NovartisEntresto | $39 | $21,51425 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $14,54229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Saginaw
- David GustavisonSaginaw$49K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.